TRS003 Bevacizumab

A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC

Study Name:
TRS003 Bevacizumab: A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC

Targeted Disease(s):
Lung Cancer

Purpose of Study:

 To demonstrate the biosimilarity, by means of investigator-determined ORR (RECIST V1.1) by week 19, of TRS003 and China-approved bevacizumab in combination with paclitaxel-carboplatin for patients with unresectable, locally, advanced, recurrent or metastatic nonsquamous NSCLC.

Study Dates:
August 1, 2020 - November 30, 2021

Study Location:
FL

Lead Institution:
BRCR medical center

Funding Source:
Zhejiang Teruisi Pharmaceutical Inc.

ClinicalTrails.gov Identifier:
NCT04416035

Contact:
Ines Padron
Contact Phone: 561-447-0614
Contact Email:ipadron@brcrglobal.com

Freedom From Smoking Clinic
, | Oct 25, 2021
Community Connections: Air Quality & Lung Disease
, | Jan 19, 2022